Nov 17, 2022
|
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
|
|
Nov 03, 2022
|
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
|
|
Nov 02, 2022
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Oct 26, 2022
|
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
|
|
Oct 17, 2022
|
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
|
|
Sep 02, 2022
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Aug 08, 2022
|
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
|
|
Jul 25, 2022
|
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
|
|
Jul 08, 2022
|
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
|
|
Jun 08, 2022
|
MacroGenics to Participate in Upcoming Investor Conference
|
|
May 23, 2022
|
MacroGenics Announces Appointment of William Heiden to Board of Directors
|
|
May 17, 2022
|
MacroGenics to Participate in Upcoming Investor Conference
|
|
May 03, 2022
|
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
|
|
Apr 25, 2022
|
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
|
|
Mar 03, 2022
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Feb 28, 2022
|
MacroGenics Announces Executive Promotion
|
|
Feb 24, 2022
|
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
|
|
Feb 14, 2022
|
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
|
|
Feb 03, 2022
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Nov 03, 2021
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Nov 02, 2021
|
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
|
|
Oct 26, 2021
|
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
|
|
Sep 16, 2021
|
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
|
|
Sep 16, 2021
|
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
|
|
Sep 12, 2021
|
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
|
|